Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
💡 한 문장 핵심
양성 전립선 비대증 치료에서 피나스테리드 사용에 관한 3년간의 안전성 및 유효성 자료.
4/5 보강
TL;DR
The excellent safety profile and sustained clinical efficacy, over thirty-six months, of daily treatment withfinasteride 5 mg recommend finasteride as a low-risk medical option for the treatment of symptomatic benign prostatic hyperplasia.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
finasteride 5 mg
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Finasteride was well tolerated and there was no evidence of increased adverse experiences with increased duration of treatment. [CONCLUSIONS] The excellent safety profile and sustained clinical efficacy, over thirty-six months, of daily treatment with finasteride 5 mg recommend finasteride as a low-risk medical option for the treatment of symptomatic benign prostatic hyperplasia.
📑 코퍼스 인용 관계
· 인용됨 14
📑 인용한 논문 (6) ▾
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the t… Therapeutic advances in urology · 2016
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A S… The Journal of clinical and aesthetic dermatology · 2016
- Persistent sexual dysfunction and depression in finasteride users for male pattern hair lo… The Journal of clinical and aesthetic dermatology · 2014
- Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Digestive diseases and sciences · 2012
- Finasteride for benign prostatic hyperplasia. The Cochrane database of systematic reviews · 2010
- Finasteride-its impact on sexual function and prostate cancer. Journal of cutaneous and aesthetic surgery · 2009
연도별 인용 (2012–2025) · 합계 31
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
Prostate Cancer Diagnosis and Treatment
Abstract 🌐 Abstract
[OBJECTIVE] To assess the long-term safety and efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia in patients treated with finasteride 5 mg for thirty-six months.
[METHODS] Two large multicenter studies were used. Patients were randomly assigned to treatment with finasteride, 1 or 5 mg, or placebo for twelve months. After completing twelve months of therapy, patients were invited to enter an open extension to the study in which all patients received finasteride 5 mg. Urinary symptoms, urinary flow rate, prostate volume, and serum concentrations of prostate-specific antigen and dihydrotestosterone were measured periodically during the study.
[RESULTS] After thirty-six months of treatment with finasteride 5 mg, prostate volume was reduced from baseline by approximately 27 percent, maximum urinary flow rate improved by approximately 2.3 mL/second, and symptom scores improved by 3.6 points. Forty-two percent of patients had a 30 percent or greater decrease in prostate volume, 40 percent of patients showed an increase of 3 mL/second or more in maximum urinary flow rate, and 48 percent of patients experienced a 50 percent or greater improvement in symptom scores. Finasteride was well tolerated and there was no evidence of increased adverse experiences with increased duration of treatment.
[CONCLUSIONS] The excellent safety profile and sustained clinical efficacy, over thirty-six months, of daily treatment with finasteride 5 mg recommend finasteride as a low-risk medical option for the treatment of symptomatic benign prostatic hyperplasia.
[METHODS] Two large multicenter studies were used. Patients were randomly assigned to treatment with finasteride, 1 or 5 mg, or placebo for twelve months. After completing twelve months of therapy, patients were invited to enter an open extension to the study in which all patients received finasteride 5 mg. Urinary symptoms, urinary flow rate, prostate volume, and serum concentrations of prostate-specific antigen and dihydrotestosterone were measured periodically during the study.
[RESULTS] After thirty-six months of treatment with finasteride 5 mg, prostate volume was reduced from baseline by approximately 27 percent, maximum urinary flow rate improved by approximately 2.3 mL/second, and symptom scores improved by 3.6 points. Forty-two percent of patients had a 30 percent or greater decrease in prostate volume, 40 percent of patients showed an increase of 3 mL/second or more in maximum urinary flow rate, and 48 percent of patients experienced a 50 percent or greater improvement in symptom scores. Finasteride was well tolerated and there was no evidence of increased adverse experiences with increased duration of treatment.
[CONCLUSIONS] The excellent safety profile and sustained clinical efficacy, over thirty-six months, of daily treatment with finasteride 5 mg recommend finasteride as a low-risk medical option for the treatment of symptomatic benign prostatic hyperplasia.
The excellent safety profile and sustained clinical efficacy, over thirty-six months, of daily treatment withfinasteride 5 mg recommend finasteride as a low-risk medical option for the treatment of sy
APA 7
Stoner, E. (1994). Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.. Urology, 43(3), 284-92; discussion 292-4. https://doi.org/10.1016/0090-4295(94)90068-x
Vancouver
Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43(3):284-92; discussion 292-4. doi:10.1016/0090-4295(94)90068-x
AMA 11
Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43(3):284-92; discussion 292-4. doi:10.1016/0090-4295(94)90068-x
Chicago
Stoner, E.. 1994. "Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia." Urology 43 (3): 284-92; discussion 292-4. https://doi.org/10.1016/0090-4295(94)90068-x
MLA 9
Stoner, E.. "Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia." Urology, vol. 43, no. 3, 1994, pp. 284-92; discussion 292-4. doi:10.1016/0090-4295(94)90068-x.
PMID
7510911 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 14
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic …
- Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year ran…
- Clinical pharmacokinetics and pharmacodynamics of finasteride.
- Finasteride for benign prostatic hyperplasia.
- Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a seri…
- Finasteride-its impact on sexual function and prostate cancer.
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
- Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
- An economic evaluation of finasteride for treatment of benign prostatic hyperplasia.
- The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen…
- Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
- Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to…
같은 제1저자의 인용 많은 논문 (5)
- The clinical development of a 5 alpha-reductase inhibitor, finasteride.
- The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
- Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
- Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
- 5alpha-reductase inhibitors/finasteride.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.